If approved, in what settings will you consider adding aglatimagene besadenovec (CAN-2409) to EBRT as an ADT-sparing strategy in prostate cancer treatment?

PrTK03 (NCT01436968; DeWeese et al., PMID 42225101) was a phase 3 RCT randomizing patients with either NCCN intermediate or high-risk prostate cancer (>1 HRF excluded) to RT ± CAN-2409, which is an adenoviral-based immunotherapy delivered with a prodrug (valacyclovir) and stratified by NCCN risk gro...

CAN-2409 "is an adenoviral replication-defective engineered gene construct, encoding the thymidine kinase gene derived from herpes simplex virus (HSV). Aglatimagene is injected directly into the tumor or target tissue...These tumor cells can then express HSV-thymidine kinase, which converts generic....